WO2008043725A1 - Biomarker in inflammatory disorders - Google Patents
Biomarker in inflammatory disorders Download PDFInfo
- Publication number
- WO2008043725A1 WO2008043725A1 PCT/EP2007/060637 EP2007060637W WO2008043725A1 WO 2008043725 A1 WO2008043725 A1 WO 2008043725A1 EP 2007060637 W EP2007060637 W EP 2007060637W WO 2008043725 A1 WO2008043725 A1 WO 2008043725A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sms2
- level
- activity
- sample
- individual
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/9015—Ligases (6)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/104—Lupus erythematosus [SLE]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/285—Demyelinating diseases; Multipel sclerosis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The use of SMS2 as a target in autoimmune disorders, e g as a biomarker, e.g. for autoimmune disorders associated wiith inflammation, such as multiple sclerosis, systemic lupus erythematosus, lupus anticoagulant, rheumatoid arthritis, inflammatory bowel disease, idiopathic thrombocytopenic purpura, autoimmune hepatitis (AHI) or fibrosis, diagnostic kits comprising SMS2 and a method for identifying agents that modulates disorders associated with elevated SMS2 levels, or SMS2 activity.
Description
Biomarker in inflammatory disorders
The present invention relates to biomarkers in inflammatory disorders, e.g. to the expression of sphingomyelin synthase enzyme 2 as a player in autoimmune diseases.
The sphingomyelin synthase enzymes (SMSs) SMS1 and SMS2 catalyse the interconversion of phosphatidylcholine and ceramide with sphingomyelin and diacylglycerol, see e.g. The Journal of Biological Chemistry VoI 281 , No. 40, pp. 29421-29425 (October 6, 2006).
We have now surprisingly found that the sphingomyelin synthase enzyme 2 (SMS2 NM_152621 ) is increased in samples from patients which are suffering from autoimmune disorders (diseases). On the other hand it was found that the sphingomyelin synthase enzyme 1 (SMS1 , NIVM47156) in the same patient samples has found to be not increased. In more detail, it was found that SMS2 expression in T cells is induced from patients with autoimmune disease, and that SMS2 expression also in B cells is induced in patients with SLE.
In several aspects the present invention provides 1. SMS2 for use, e.g., or the use of SMS2, e.g. SMS2 in human CD3+ cells, 1.1 as a target in immune, e.g. autoimmune, disorders; such as immune disorders in humans;
1.2 for diagnosing disorders mediated, e.g. associated with, e.g. driven by, elevated levels of SMS2, e.g. or SMS2 activity, such as for diagnosing immune, e.g. autoimmune, disorders, e.g. autoimmune disorders in humans. 1.3 for diagnosing Multiple Sclerosis (MS), Systemic Lupus Erythematosus (SLE), Lupus Anticoagulant (LA), Rheumatoid Arthritis (RA) or Idiopathic Thrombocytopenic Purpura (ITP).
Preferably disorders according to the present invention are disorders mediated, e.g. associated with, e.g. driven by, elevated levels of SMS2.
Elevated levels of SMS2 include levels which are elevated at least 2-fold up to 30-fold and more, e.g. 3-fold to 30-fold, such as 3-fold to 20-fold.
Since, according to the present invention it is shown that the amount of SMS2 in a sample from a patient suffering from an (auto)ιmmune disorder is elevated, it reasonably may be concluded that also SMS2 activity plays a role in (auto)ιmmune disorders, e g a higher amount of SMS2 is related with higher activity of SMS2
"SMS2" as used herein is to be understood as sphingomyelin synthase enzyme 2 Disorders as used herein include diseases
Disorders mediated, e g associated with, e g driven by , elevated levels of SMS2, e g or SMS2 activity, include immune, such as autoimmune disorders, e g such as autoimmune disorders associated with inflammation, e g Multiple Sclerosis (MS), Systemic Lupus Erythematosus (SLE), Lupus Anticoagulant (LA), Rheumatoid Arthritis (RA), Idiopathic Thrombocytopenic Purpura (ITP), inflammatory bowel disease (IBD), autoimmune hepatitis (AHI) and fibrosis, such as MS, SLE, LA, RA and/or ITP
in another aspect the present invention provides
1 3 SMS2 for use, e g , or the use of SMS2, for diagnosing Multiple Sclerosis (MS),
Systemic Lupus Erythematosus (SLE), Lupus Anticoagulant (LA), Rheumatoid Arthritis (RA), Idiopathic Thrombocytopenic Purpura (ITP), inflammatory bowel disease (IBD), autoimmune hepatitis (AHI) and/or fibrosis, such as MS, SLE, LA, RA and/or ITP
In several other aspects the present invention further provides
2 SMS2, e g or the use of SMS2, as a biomarker, for a use as indicated under 1 1 to 1 3 above, e g in a sample of an individual, e g in a sample of a body fluid or a tissue sample of an individual,
SMS2 as indicated under any of 1 or 2 above includes SMS2 in CD3+ cells
Expression profiling in CD3+ cells revealed that levels of SMS2 mRNA, but not of SMS1 nRNA, are significantly elevated in SLE (14-fold, p<0 0001 ), RA (8-fold, p<0 01 ), MS (17- fold, p<0 0001 ), and ITP (15-fold, p<0 01 ) patients in comparison to the control ND (healthy donor) group In LA patients a tendency for an up-regulated expression of SMS2 is observed (4-fold, p=0 053)
SMS2 as indicated herein includes SMS2 in any form, e.g. in the form of
- a nucleic acid encoding SMS2, e.g. including a nucleic acid encoding a derivative of SMS2,
- SMS2 protein, e.g. including protein which is SMS2 or a derivative thereof, or
- SMS2 secreting cells, e.g. or a derivative of SMS2 secreting cells.
"A derivative" of SMS2 nucleic acid or protein, e.g. in secreting cells, according to the present invention includes a fragment, a mutant, a variant, an homolog or a modification of a SMS2 protein, or of a nucleic acid encoding SMS2 which retains, e.g. essentially, the biological function of SMS2, e.g. which retains, e.g. essentially, the biological function of SMS2, e.g. in dendritic cells.
SMS2 containing cells, e.g. including SMS2 producing cells, e.g. include CD3+ cells.
Thus, SMS2 for use as provided by the present invention includes splice variants encoded by mRNA generated by alternative splicing of a primary transcript, amino acid mutants, posttranslational modifications, such as glycosylation and phosphorylation variants, and modifications which are covalent derivatives of SMS2 and which retain the biological function of SMS2, e.g. in CD3+ cells. Exemplary SMS2 derivatives include modifications wherein the SMS2 protein is covalently modified by substitution, e.g. substitution originating from appropriate means, e.g. chemical or enzymatic means, by a moiety in the SMS2 protein. Such a moiety e.g. includes one or more amino acids, e.g. naturally occurring amino acids and other than naturally occurring amino acids, and/or a detectable moiety. A detectable moiety includes an enzyme, a radioisotope, tags, toxins and genes such as oncogenes and tumour suppressor genes. SMS2 derivatives further includ naturally occurring variants of SMS2, e.g. provided within a particular species. Such a variant may be encoded by a related gene of the same gene family, by an allelic variant of a particular gene, or represent an alternative splicing variant of the SMS2 gene.
A SMS2 derivative as used herein also includes fragments of a nucleic acid encoding SMS2, or of the SMS2 protein, and comprises individual SMS2 domains and smaller polypeptides derived from SMS2 domains. Preferably, smaller polypeptides derived from SMS2 according to the invention define a single functional activity which is characteristic of SMS2. Fragments may in theory be of almost any size, as long as they retain the biological characteristic of SMS2. Preferably, fragments will be between 12 and 210 nucleic acids in length or between
4 and 70 amino acids, respectively. Longer fragments are regarded as truncations of the full- length SMS2.
Derivatives of SMS2 as used herein also comprise mutants thereof, which may contain amino acid deletions, additions or substitutions, subject to the requirement to retain the biological function of SMS2, e.g. in CD3+ cells. Conservative amino acid substitutions may be made substantially without altering the nature of SMS2, e.g. by truncations from the 5' or 3' ends. Deletions and substitutions also include deletions and substitutions in fragments of SMS2. SMS2 mutants may be produced from a DNA encoding SMS2 which has been subjected to in vitro mutagenesis resulting e.g. in an addition, exchange and/or deletion of one or more amino acids in SMS2. For example, substitutional, deletional or insertional variants of SMS2 can be prepared by recombinant methods and screened for functional similarity to the native forms of SMS2.
Derivatives of SMS2 as used herein also include SMS2 homologs, preferably SMS2 homologs retain substantial homology with SMS2. As used herein, "homology" means that SMS2and a SMS2 homolog share sufficient characteristics to retain the biological function of SMS2, e.g. in CD3+ cells. Preferably, homology is used to refer to sequence identity. Thus, the derivatives of SMS2 preferably retain substantial sequence identity with the nucleic acid sequence as given in
"Substantial homology", where homology indicates sequence identity, means more than 50% sequence identity, preferably more than 75% sequence identity and even more preferably a sequence identity of 80% and more, e.g. 90% and more, such as 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%..
Preferably SMS2 is originating from a mammal, e.g. a human.
The nucleic acid encoding SMS2 preferably has the nucleic acid sequence as disclosed in literature for SMS2, such as NM_152621. The SMS2 protein preferably corresponds to the translated protein sequence of the above mentioned nucleic acid.
Biomarker as used herein means that determination (= detection and/or quantification) of a SMS2 molecule in a sample of an individual is an indicator for a disorder or disease as such and/or is useful for monitoring the status of a disorder or disease related with SMS2 activity.
In another aspect the present invention provides a method for diagnosing a disorder which is mediated, e g associated with, e g driven by, elevated levels of SMS2, e g or SMS2 activity, comprising a) providing a sample of an individual, b) determining the level of SMS2 in said sample, e g the level of mRNA of SMS2, e g in CD3+ cells, c) comparing the level of SMS2 as determined in step b) with a reference level from a sample of a healthy control individual, and d) diagnosing a disorder or disease which is mediated, e g associated with, e g driven by, elevated levels of SMS2, e g or SMS2 activity, by determination whether the level of
SMS2 as determined in step b) is, e g significantly, different from said reference level
In another aspect the present invention provides a method for monitoring the therapeutic efficacy in the treatment of an individual with a substance which is expected to have an effect on reducing or curing a disorder or disease which is mediated, e g associated with, e g driven by, elevated levels of SMS2, e g or SMS2 activity, which method comprises determining the level of SMS2 in cells, e g CD3+ cells, in a sample of said individual and comparing that level with the level of SMS2 prior to administration of said substance
A sample of an individual according to a use or a method of the present invention includes a sample of a body fluid or a tissue sample A body fluid may be derived e g from blood, e g including isolated mononuclear cells, or from a blood fraction, e g including plasma or serum, preferably serum A tissue sample may be a biopsy, e g such as a skin biopsy
In another aspect the present invention provides the a use or a method of the present invention wherein a sample is a body fluid or a tissue sample of an individual, e g a body fluid may be derived from blood, e g isolated cells, such as CD3+ cells, or from a blood fraction, e g plasma or serum, e g serum, e g the tissue sample may be a biopsy, e g such as a skin biopsy
Cells, e g CD3+ cells from a sample of an individual may be isolated as appropriate, e g according, e g analogously, to a a method as conventional
Detection means in cells for determining the level of SMS2 include means as conventional, e g immunoassays, such as an immunodiagnostic method, an enzyme linked immunoassay
(ELISAs), a fluorescence based assay, such as dissociation enhanced lanthanide fluoroimmunoassay (DELFIA), an radiometric assay or by carrying out a SMS2 specific Polymerase Chain Reaction (PCR) Specifically, detection means include a molecule which specifically recognizes SMS2, e g a molecule which is directly or indirectly detectable, preferably comprising an antibody, including antibody derivatives or fragments thereof, e g an antibody which recognizes SMS2, e g a label bearing SMS2 recognizing antibody Such label may be a conventional label, e g biotin or an enzyme such as alkaline phosphatase (AP), horse radish peroxidase (HRP) or peroxidase (POD) or a fluorescent molecule, e g a fluorescent dye, such as e g fluorescein isothiocyanate Preferably the label is biotin The label bearing molecule, e g the label bearing antibody, may be detected according to methods as conventional, e g via fluorescence measurement or enzyme detection methods
An antibody fragment or antibody derivative includes a fragment or a derivative, e g chemically or enzymatically modified, of an antibody which still is capable of recognising SMS2
SMS2 -secreting cells in a sample of a body fluid of an individual, e g blood, may be determined by a method as conventional, e g by the following method Cells, e g dendritic cells may be purified, e g separated by a density gradient, from the sample, e g blood, and the purified cells obtained are stained Anti- SMS2 antibodies, e g fluorescence labeled anti- SMS2 antibodies, are added to the stained cell preparation, optionally after stimulation of the cells, e g with ιnterleukιn-4, and the level of SMS2- secreting cells is determined
Optionally, SMS2 comprised in the sample or the SMS2 recognizing, e g detectable, molecule comprised in the detection means is immobilized on a solid phase An appropriate solid phase includes e g conventional solid phases used for immobilization, e g a plastic plate like a polystyrene or polyvinyl plate, especially a microtiter plate Also microbeads can be used as a solid phase, e g coated microbeads The solid phase can be coated with a coating material the nature of which depends e g on the label comprised in the detection means The coating material should be able to bind to the label, e g if the label is biotin a coating material includes streptavidin, e g covalently bound to the solid phase Preferably determination of SMS2 in cells, e g CD3+ cells, is carried out by PCR
In another aspect the present invention provides a method for diagnosing a disorder or disease which is mediated, e g associated with, e g driven, by elevated levels of SMS2 activity according to the present invention wherein the level of SMS2 in cells, e g in CD3+ cells, is determined by use of by PCR
In another aspect the present invention provides the a kit, comprising a) a molecule which recognizes SMS2, optionally in a labeled form, b) instructions how to use said kit, e g in CD3+ cell isolates, c) optionally detection means, d) optionally a solid phase, for diagnosing a disorder which is mediated, e g associated with, e g driven, by elevated levels of SMS2, e g or SMS2 activity, in a sample of an individual
In another aspect the present invention provides the use of a kit, comprising a) a molecule which recognizes SMS2, optionally in a labeled form, b) instructions how to use said kit, e g in CD3+ cell isolates, c) optionally detection means, d) optionally a solid phase, for diagnosing a disorder or disease which is mediated, e g associated with, e g driven, by elevated levels of SMS2, e g or SMS2 activity, in a sample of an individual
Such kit may further comprise a substantial component, e g including an appropriate environment of a sample to be tested and, e g appropriate means to determine SMS2 in a sample to be tested
In another aspect the present invention provides a method for the preparation of a kit by provision of a) a molecule which recognizes SMS2, optionally in a labeled form, b) instructions how to use said kit, e g in CD3+ cell isolates, c) optionally detection means, d) optionally a solid phase, for diagnosing a disorder or disease which is mediated, e g associated with, e g driven, by elevated levels of SMS2, e g or SMS2 activity, in a sample of an individual
In a further aspect the present invention provides an assay for identifying an agent that mediates a disorder which is mediated by elevated SMS2 level, e g or SMS2 activity, comprising a) determining the level of SMS2, e g in CD3+ cells of a sample of an individual, in the absence and in the presence of a candidate compound which may be expected to modulate the level of SMS2, b) identifying a candidate compound which modulates the level of SMS2 as determined in step a) as an agent, e g and c) using such agent as a pharmaceutical in the treatment of disorders or diseases mediated, e g associated with, e g driven, by elevated levels of SMS2, e g or SMS2 activity
Preferably a candidate compound identified decreases the level of SMS2 The level of SMS2 is determined as appropriate, e g as described herein
A candidate compound as described herein is a compound which may be expected to modulate the level of SMS2, or SMS2 activity or SMS2 secreting cells, and includes compound(s)(lιbraπes) from which its influence on SMS2 can be determined Compound (libraries) include for example oligopeptides, polypeptides, proteins, antibodies, mimetics, small molecules, e g low molecular weight compounds (LMW's)
An agent is a candidate compound which modulates the level of the level of SMS2, or SMS2 activity or SMS2 secreting cells, e g in cells, such as CD3+ cells in a sample form a patient, e g a blood sample, such as serum, e g or a skin biopsy An agent includes oligopeptides, polypeptides, proteins, antibodies, mimetics, small molecules, e g low molecular weight compounds (LMWs)
In another aspect the present invention provides an agent identified by an assay or a method of the present invention
An agent of the present invention may exhibit pharmacological activity and is therefore useful as a pharmaceutical An agent of the present invention may show therapeutic activity, e g in disorders or diseases mediated, e g associated with, e g driven by elevated levels of SMS2, or SMS2 activity
In another aspect the present invention provides the use of an agent of the present invention as a pharmaceutical in disorders mediated, e g associated with, e g driven by elevated levels of SMS2, e g or SMS2 activity
For pharmaceutical use an agent of the present invention for treatment includes one or more, preferably one, agent of the present invention, e g a combination of two or more agents of the present invention
In another aspect the present invention provides the use of an agent of the present invention for the manufacture of a medicament for the treatment of disorders or diseases mediated, e g associated with, e g driven by SMS2 activity
In another aspect the present invention provides a pharmaceutical composition comprising an agent of the present invention beside at least one pharmaceutical excipient, e g appropriate carrier and/or diluent, e g including fillers, binders, disintegrators, flow conditioners, lubricants, sugars and sweeteners, fragrances, preservatives, stabilizers, wetting agents and/or emulsifiers, solubilizers, salts for regulating osmotic pressure and/or buffers
In another aspect the present invention provides a method for the treatment of disorders or diseases mediated, e g associated with, e g driven, by elevated SMS2 levels, e g or SMS2 activity, comprising administering an effective amount of an agent of the present invention to a subject in need of such treatment
For such treatment, the appropriate dosage will, of course, vary depending upon, for example, the chemical nature and the pharmakokinetic data of a compound of the present invention used, the individual host, the mode of administration and the nature and severity of the conditions being treated However, in general, for satisfactory results in larger mammals, for example humans, an indicated daily dosage includes a range - from about 0 001 g to about 1 5 g, such as 0 001 g to 1 5 g,
- from about 0 01 mg/kg body weight to about 20 mg/kg body weight, such as 0 01 mg/kg body weight to 20 mg/kg body weight, for example administered in divided doses up to four times a day
An agent of the present invention may be administered by any conventional route, for example enterally, e g including nasal, buccal, rectal, oral, administration, parenterally, e g including intravenous, intramuscular, subcutanous administration, or topically, e g including epicutaneous, intranasal, intratracheal administration, via medical devices for local delivery, e g stents, e g in form of coated or uncoated tablets, capsules, (injectable) solutions, solid solutions, suspensions, dispersions, solid dispersions, e g in the form of ampoules, vials, in the form of creams, gels, pastes, inhaler powder, foams, tinctures, lip sticks, drops, sprays, or in the form of suppositories For topical use, e g including administration to the eye, satisfactory results may be obtained with local administration of a 0 5-10 %, such as 1-3% concentration of active substance several times daily, e g 2 to 5 times daily
An agent of the present invention may be administered in the form of a pharmaceutically acceptable salt, e g an acid addition salt or metal salt, or in free form, optionally in the form of a solvate An agent of the present invention in the form of a salt may exhibit the same order of activity as an agent of the present invention in free form, optionally in the form of a solvate
An agent of the present invention may be used for pharmaceutical treatment according to the present invention alone, or in combination with one or more other pharmaceutically active agents
Combinations include fixed combinations, in which two or more pharmaceutically active agents are in the same formulation, kits, in which two or more pharmaceutically active agents in separate formulations are sold in the same package, e g with instruction for coadministration, and free combinations in which the pharmaceutically active agents are packaged separately, but instruction for simultaneous or sequential administration are given
Description of the Figures Figure 1
Shows the relative expression of SMS2 mRNA in CD3+ cells of patients with autoimmune diseases compared with healthy donors (ND)
From Figure 1 it is evident that in patients with autoimmune disease the expression of SMS2 mRNA in CD3+ cells is remarkably increased compared with healthy donors (ND)
Figure 2
Shows the relative expression of SMS1 mRNA in CD3+ cells of patients with autoimmune diseases compared with healthy donors (ND) From Figure 2 it is evident that in patients with autoimmune disease the expression of SMS1 mRNA in CD3+ cells is practically not increased compared with healthy donors (ND)
In sum, according to the present invention SMS2 mRNA expression, but not SMS1 mRNA expression in cells, such as in CD3+ cells, has been found to be associated with autoimmune disorders
Claims
Patent Claims
1 The use of SMS2 as a target in immune disorders
2 The use of SMS2 for diagnosing disorders associated with elevated levels of SMS2, or SMS2 activity
3 The use of SMS2 as a biomarker for a use as claimed in any one of claims 1 or 2
4 The use according to any one of claims 1 to 3 wherein SMS2 is used as a biomarker for immune disorders
5 The use according to any one of claims 1 to 4 wherein SMS2 is used as a biomarker for Multiple Sclerosis (MS), Systemic Lupus Erythematosus (SLE), Lupus Anticoagulant
(LA), Rheumatoid Arthritis (RA), Idiopathic Thrombocytopenic Purpura (ITP), inflammatory bowel disease (IBD), autoimmune hepatitis (AHI) and/or fibrosis
6 A method for diagnosing a disorder which is associated with elevated levels of SMS2, or SMS2 activity, comprising a) providing a sample of an individual, b) determining the level of SMS2 in said sample, c) comparing the level of SMS2 as determined in step b) with a reference level from a sample of a healthy control individual, and d) diagnosing a disorder or disease which is associated with elevated levels of SMS2, or SMS2 activity, by determination whether the level of SMS2 as determined in step b) is different from said reference level
7 A method for monitoring the therapeutic efficacy in the treatment of an individual with a substance which is expected to have an effect on reducing or curing a disorder which is associated with elevated levels of SMS2, or SMS2 activity, which method comprises determining the level of SMS2 in cells in a sample from said individual and comparing that level with the level of SMS2 prior to administration of said substance
8. A kit for diagnosing of a disorder or disease which is mediated by SMS2 in a sample of an individual comprising a) a molecule which recognizes SMS2, optionally in a labeled form, b) instructions how to use said kit, c) optionally detection means, d) optionally a solid phase.
9. An assay for identifying an agent that mediates a disorder which is mediated by elevated SMS2 levels, or SMS2 activity, comprising a) determining the level of SMS2 in the absence and in the presence of a candidate compound which may be expected to modulate the level of SMS2, b) identifying a candidate compound which modulates the level of SMS2 as determined in step a) as an agent, and, optionally, c) using such agent as a pharmaceutical in the treatment of disorders or diseases associated with elevated levels of SMS2, e.g. or SMS2 activity.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06122039.8 | 2006-10-10 | ||
| EP06122039 | 2006-10-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2008043725A1 true WO2008043725A1 (en) | 2008-04-17 |
Family
ID=37569639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2007/060637 WO2008043725A1 (en) | 2006-10-10 | 2007-10-08 | Biomarker in inflammatory disorders |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2008043725A1 (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012012725A2 (en) | 2010-07-23 | 2012-01-26 | President And Fellows Of Harvard College | Methods of detecting diseases or conditions using phagocytic cells |
| US10295527B2 (en) | 2016-03-14 | 2019-05-21 | Bruce Yacyshyn | Process and system for predicting responders and non-responders to mesalamine treatment of ulcerative colitis |
| US10494675B2 (en) | 2013-03-09 | 2019-12-03 | Cell Mdx, Llc | Methods of detecting cancer |
| US10626464B2 (en) | 2014-09-11 | 2020-04-21 | Cell Mdx, Llc | Methods of detecting prostate cancer |
| CN111481548A (en) * | 2019-01-29 | 2020-08-04 | 复旦大学 | Application of 4- (2, 6-dichlorobenzyloxy) -3- (3-aminopyridine) benzo [ d ] isoxazole in pharmacy |
| US10934589B2 (en) | 2008-01-18 | 2021-03-02 | President And Fellows Of Harvard College | Methods of detecting signatures of disease or conditions in bodily fluids |
| US10961578B2 (en) | 2010-07-23 | 2021-03-30 | President And Fellows Of Harvard College | Methods of detecting prenatal or pregnancy-related diseases or conditions |
| US11111537B2 (en) | 2010-07-23 | 2021-09-07 | President And Fellows Of Harvard College | Methods of detecting autoimmune or immune-related diseases or conditions |
| US11585814B2 (en) | 2013-03-09 | 2023-02-21 | Immunis.Ai, Inc. | Methods of detecting prostate cancer |
| EP4303584A2 (en) | 2010-07-23 | 2024-01-10 | President and Fellows of Harvard College | Methods for detecting signatures of disease or conditions in bodily fluids |
| US11946927B2 (en) | 2016-03-14 | 2024-04-02 | Musidora Biotechnology Llc | Process and system for identifying individuals having a high risk of inflammatory bowel disease and a method of treatment |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005003336A2 (en) * | 2003-07-07 | 2005-01-13 | Universiteit Utrecht Holding B.V. | Newly identified cholinephosphotransferases and ethanolaminephosphotransferases |
-
2007
- 2007-10-08 WO PCT/EP2007/060637 patent/WO2008043725A1/en active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005003336A2 (en) * | 2003-07-07 | 2005-01-13 | Universiteit Utrecht Holding B.V. | Newly identified cholinephosphotransferases and ethanolaminephosphotransferases |
| US20060205031A1 (en) * | 2003-07-07 | 2006-09-14 | 1) Universiteit Utrecht Holding B.V. | Newly identified cholinephosphotransferases and ethanolaminephosphotransferases |
Non-Patent Citations (2)
| Title |
|---|
| DONG JIBIN ET AL: "Adenovirus-mediated overexpression of sphingomyelin synthases 1 and 2 increases the atherogenic potential in mice.", JOURNAL OF LIPID RESEARCH JUN 2006, vol. 47, no. 6, June 2006 (2006-06-01), pages 1307 - 1314, XP002459535, ISSN: 0022-2275 * |
| HUITEMA K ET AL: "Identification of a family of animal sphingomyelin synthases", EMBO JOURNAL, IRL PRESS, EYNSHAM, GB, vol. 23, no. 1, 14 January 2004 (2004-01-14), pages 33 - 44, XP002325870, ISSN: 0261-4189 * |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10934589B2 (en) | 2008-01-18 | 2021-03-02 | President And Fellows Of Harvard College | Methods of detecting signatures of disease or conditions in bodily fluids |
| US11001894B2 (en) | 2008-01-18 | 2021-05-11 | President And Fellows Of Harvard College | Methods of detecting signatures of disease or conditions in bodily fluids |
| US10934588B2 (en) | 2008-01-18 | 2021-03-02 | President And Fellows Of Harvard College | Methods of detecting signatures of disease or conditions in bodily fluids |
| US11111537B2 (en) | 2010-07-23 | 2021-09-07 | President And Fellows Of Harvard College | Methods of detecting autoimmune or immune-related diseases or conditions |
| US10961578B2 (en) | 2010-07-23 | 2021-03-30 | President And Fellows Of Harvard College | Methods of detecting prenatal or pregnancy-related diseases or conditions |
| WO2012012725A2 (en) | 2010-07-23 | 2012-01-26 | President And Fellows Of Harvard College | Methods of detecting diseases or conditions using phagocytic cells |
| EP4303584A2 (en) | 2010-07-23 | 2024-01-10 | President and Fellows of Harvard College | Methods for detecting signatures of disease or conditions in bodily fluids |
| US10494675B2 (en) | 2013-03-09 | 2019-12-03 | Cell Mdx, Llc | Methods of detecting cancer |
| US11585814B2 (en) | 2013-03-09 | 2023-02-21 | Immunis.Ai, Inc. | Methods of detecting prostate cancer |
| US10626464B2 (en) | 2014-09-11 | 2020-04-21 | Cell Mdx, Llc | Methods of detecting prostate cancer |
| US10295527B2 (en) | 2016-03-14 | 2019-05-21 | Bruce Yacyshyn | Process and system for predicting responders and non-responders to mesalamine treatment of ulcerative colitis |
| US11199534B2 (en) | 2016-03-14 | 2021-12-14 | Bruce Yacyshyn | Process and system for predicting responders and non-responders to mesalamine treatment of ulcerative colitis |
| US11946927B2 (en) | 2016-03-14 | 2024-04-02 | Musidora Biotechnology Llc | Process and system for identifying individuals having a high risk of inflammatory bowel disease and a method of treatment |
| CN111481548A (en) * | 2019-01-29 | 2020-08-04 | 复旦大学 | Application of 4- (2, 6-dichlorobenzyloxy) -3- (3-aminopyridine) benzo [ d ] isoxazole in pharmacy |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008043725A1 (en) | Biomarker in inflammatory disorders | |
| US20100029007A1 (en) | Biomarker in Inflammatory Diseases | |
| JP2002098702A (en) | Method for identifying compound useful for therapy of morbidity mediated by prostaglandin d2 | |
| JP5701994B2 (en) | Citrullinated proteins: post-translational modification of myocardial proteins as markers of physiological and pathological diseases | |
| Benna et al. | P40phox associates with the neutrophil Triton X-100-insoluble cytoskeletal fraction and PMA-activated membrane skeleton: a comparative study with P67phox and P47phox | |
| WO2000062076A1 (en) | Galectin expression is induced in cirrhotic liver and hepatocellular carcinoma | |
| US20200138951A1 (en) | Fkbp52-tau interaction as a novel therapeutical target for treating the neurological disorders involving tau dysfunction | |
| EP1843781B1 (en) | Composition for prevention, treatment and diagnosis of chronic inflammatory airway diseases | |
| WO2010121714A1 (en) | Complexes between phospholipids and protein vimentin, and in vitro methods for the detection of antibodies against these complexes | |
| EP1287020A2 (en) | Cancer diagnosis and assays for screening anti-cancer agents | |
| EP1880219B1 (en) | Gpr18 as a biomaker for th1 mediated immune response | |
| BR112014002747A2 (en) | method for measuring an anti-wt1 antibody | |
| CN114591418A (en) | Threonine 166 th phosphorylation modification of PPAR gamma protein and application thereof | |
| BRPI0511489B1 (en) | Relative risk assessment method of developing atherosclerosis in patients | |
| US20140004530A1 (en) | Method for the evaluation of compound-target interactions across species | |
| US20070254303A1 (en) | Methods for assessing the efficacy of treatment with a glucocorticoid | |
| KR20140109956A (en) | Tenascin-c and use thereof in rheumatoid arthritis | |
| KR20140074559A (en) | A Kit for Diagnosing the Cardiovascular Disease | |
| KR102346644B1 (en) | Method for screening biomarkers diagnosing cardiovascular diseases, biomarkers screened thereby and method for diagnosing cardiovascular diseases using the same | |
| WO2021245413A1 (en) | Methods of determining cancer | |
| EP2482074A1 (en) | Methods and means for diagnosing vasculitis | |
| US8313917B2 (en) | Methods of diagnosing latent and active malignancies | |
| JP2023526144A (en) | Assays for immune cell recovery | |
| JP2019190883A (en) | New lung cancer marker | |
| EP2558856B1 (en) | Method for diagnosis of multiple sclerosis involving anti-at1-receptor antibody |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07821010 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 07821010 Country of ref document: EP Kind code of ref document: A1 |